Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors

September 30, 2019
David S. Hong, MD

David S. Hong, MD, discusses&nbsp;updated data with larotrectinib (Vitrakvi) in&nbsp;<em>TRK</em>&nbsp;fusion-positive solid tumors at the ESMO Congress 2019.&nbsp;

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated data with larotrectinib (Vitrakvi) in TRKfusion-positive solid tumors at the ESMO Congress 2019.

The tumor-agnostic TRK inhibitor larotrectinib showed sustained antitumor activity in adult and pediatric patients withTRKfusion—positive cancers, based on updated findings from an integrated analysis of an adult phase I trial, the phase I/II SCOUT pediatric trial, and the phase II adult/adolescent NAVIGATE basket trial.